Northeast Pharmaceutical Group Dirección

Dirección controles de criterios 2/4

El CEO de Northeast Pharmaceutical Group es Zhou Kai, nombrado en May 2019, tiene una permanencia de 5.5 años. posee directamente un 0.3% de las acciones de la empresa, con un valor de CN¥21.65M. La antigüedad media del equipo directivo y de la junta directiva es de 1.3 años y 5 años, respectivamente.

Información clave

Zhou Kai

Chief Executive Officer (CEO)

CN¥1.8m

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	5.5yrs
Participación del CEO	0.3%
Permanencia media de la dirección	1.3yrs
Promedio de permanencia en la Junta Directiva	5yrs

Actualizaciones recientes de la dirección

Recent updates

CEO

Zhou Kai (60 yo)

5.5yrs

Permanencia

CN¥1,824,100

Compensación

Mr. Zhou Kai serves as a General Manager of Northeast Pharmaceutical Group Co., Ltd. since May 8, 2019 and serves its Non-Independent Director since November 29, 2020. He served as a Vice President of Nort...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Zhou Kai	GM & Director	5.5yrs	CN¥1.82m	0.30% CN¥ 21.6m
Jialun Song	Financial Director & Secretary	1.8yrs	CN¥2.14m	0.022% CN¥ 1.6m
Xiao Feng	Deputy General Manager	less than a year	CN¥894.30k	sin datos
Yonggang Cai	Deputy General Manager	less than a year	sin datos	sin datos

1.3yrs

Permanencia media

51.5yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de 000597 no se considera experimentado ( 1.3 años antigüedad media), lo que sugiere un nuevo equipo.

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Zhou Kai	GM & Director	4yrs	CN¥1.82m	0.30% CN¥ 21.6m
Demin Han	Independent Director	6.3yrs	CN¥150.00k	sin datos
Zhaochun Tan	Non-Independent Director	3yrs	sin datos	sin datos
Chengren Huang	Non-Independent Director	6.3yrs	sin datos	0.23% CN¥ 16.5m
Xinhua Ao	Non-Independent Director	6.3yrs	sin datos	0.23% CN¥ 16.5m
Guodong Wang	Independent Director	6.3yrs	CN¥150.00k	sin datos
Hui Yao	Independent Director	6.3yrs	CN¥150.00k	sin datos
Youguang Shang	Independent Director	4.1yrs	CN¥150.00k	sin datos
Jianmin Guo	Chairman of the Board	3.1yrs	CN¥2.07m	0.22% CN¥ 16.4m
Zhihua Huang	Non-Independent Director	3yrs	sin datos	0.070% CN¥ 5.1m
Baidan Zhan	Chairman of the Supervisory Board	5.9yrs	sin datos	sin datos
Hai Tian	Director	1.2yrs	sin datos	sin datos

5.0yrs

Permanencia media

59yo

Promedio de edad

Junta con experiencia: La junta directiva de 000597 se considera experimentada (5 años de antigüedad promedio).

Northeast Pharmaceutical Group Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

Northeast Pharmaceutical Group Co., Ltd., Annual General Meeting, Apr 19, 2024

High number of new directors

High number of new directors

High number of new directors

High number of new directors

Northeast Pharmaceutical Group Co., Ltd., Annual General Meeting, Apr 06, 2021

Recent updates

Now 21% undervalued

Investor sentiment improves as stock rises 22%

Third quarter 2024 earnings released: EPS: CN¥0.036 (vs CN¥0.059 in 3Q 2023)

Investor sentiment improves as stock rises 19%

Northeast Pharmaceutical Group Co., Ltd. to Report Q3, 2024 Results on Oct 24, 2024

New minor risk - Earnings quality

Second quarter 2024 earnings released: EPS: CN¥0.07 (vs CN¥0.045 in 2Q 2023)

Investor sentiment deteriorates as stock falls 22%

New minor risk - Share price stability

Northeast Pharmaceutical Group Co., Ltd. to Report First Half, 2024 Results on Aug 28, 2024

Dividend of CN¥0.10 announced

Northeast Pharmaceutical Group Co., Ltd. Implements 2023 Final Cash Profit Distribution Plan, Payable on 23 May 2024

New minor risk - Earnings quality

First quarter 2024 earnings released: EPS: CN¥0.04 (vs CN¥0.049 in 1Q 2023)

Full year 2023 earnings released: EPS: CN¥0.25 (vs CN¥0.25 in FY 2022)

Northeast Pharmaceutical Group Co., Ltd., Annual General Meeting, Apr 19, 2024

Investor sentiment deteriorates as stock falls 18%

Northeast Pharmaceutical Group Co., Ltd. to Report Fiscal Year 2023 Results on Mar 30, 2024

High number of new directors

Third quarter 2023 earnings released: EPS: CN¥0.059 (vs CN¥0.011 in 3Q 2022)

Second quarter 2023 earnings released: EPS: CN¥0.045 (vs CN¥0.033 in 2Q 2022)

Now 21% undervalued after recent price drop

Northeast Pharmaceutical Group Co., Ltd. to Report First Half, 2023 Results on Aug 23, 2023

Now 21% undervalued after recent price drop

Northeast Pharmaceutical Group Co., Ltd. Announces 2022 Final Cash Profit Distribution Plan, Payable on 16 May 2023

Full year 2022 earnings released: EPS: CN¥0.25 (vs CN¥0.07 in FY 2021)

Now 21% undervalued

Now 21% undervalued

Now 21% undervalued

Investor sentiment improved over the past week

High number of new directors

Third quarter 2022 earnings released: EPS: CN¥0.011 (vs CN¥0.026 loss in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥0.033 (vs CN¥0.016 in 2Q 2021)

High number of new directors

Northeast Pharmaceutical Group Co., Ltd. Proposes Final Dividend for the Year 2021, Payable on 27 May 2022

First quarter 2022 earnings released: EPS: CN¥0.051 (vs CN¥0.029 in 1Q 2021)

Northeast Pharmaceutical Group Co., Ltd. Approves the Profit Distribution for 2021

Full year 2021 earnings released: EPS: CN¥0.07 (vs CN¥0.01 in FY 2020)

Northeast Pharmaceutical Group Co., Ltd. Proposes Cash Dividend for 2021

High number of new directors

Third quarter 2021 earnings released: CN¥0.026 loss per share (vs CN¥0.042 loss in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.016 (vs CN¥0.063 in 2Q 2020)

Northeast Pharmaceutical Group Co., Ltd. Announces Final Cash Dividend of A Shares, Payable on 27 May 2021

First quarter 2021 earnings released: EPS CN¥0.029 (vs CN¥0.013 loss in 1Q 2020)

Full year 2020 earnings released: EPS CN¥0.01 (vs CN¥0.13 in FY 2019)

Northeast Pharmaceutical Group Co., Ltd. Proposes Final Cash Dividend for the Year 2020

Northeast Pharmaceutical Group Co., Ltd., Annual General Meeting, Apr 06, 2021

Northeast Pharmaceutical Group Co., Ltd. to Report Fiscal Year 2020 Results on Mar 17, 2021

New 90-day low: CN¥4.86

New 90-day low: CN¥5.03

New 90-day low: CN¥5.37

New 90-day low: CN¥5.39

Third quarter earnings released

Northeast Pharmaceutical Group Co., Ltd. to Report Q3, 2020 Results on Oct 27, 2020

Jiangxi Fangda Steel Technology Co., Ltd. completed the acquisition of an additional 10% stake in Northeast Pharmaceutical Group Co., Ltd. (SZSE:000597) for approximately CNY 890 million.

Northeast Pharmaceutical Group Co., Ltd. announced that it expects to receive CNY 2 billion in funding from Joyvio Group Co., Ltd., Liaoning Fangda Group Industrial Co., Ltd., and other investors

First half earnings released

New 90-day high - CN¥6.15

New 90-day high - CN¥6.02

Northeast Pharmaceutical Group Co., Ltd. to Report First Half, 2020 Results on Aug 25, 2020

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad